logo

For the Inventor, By the Inventor

Chesterfield, MO, United States of America

Jeffery S Carter

USPTO Granted Patents = 34

 

Average Co-Inventor Count = 6.5

ph-index = 14

Forward Citations = 761(Granted Patents)


Company Filing History:

goldMedal20 out of 1,323 
 
G.d. Searle & Company
 patents
silverMedal11 out of 200 
 
Pharmacia Corporation
 patents
bronzeMedal1 out of 5 
 
Pharmacia Corporation (of Pfizer, Inc.)
 patents
4. 2 out of 832,843 
Other
 patents

Years Active: 1995-2008

Loading Chart...
Loading Chart...
34 patents (USPTO):Explore Patents
1. 7420061 - Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors (2008-09-02),
2. 7138411 - Substituted benzopyran derivatives for the treatment of inflammation (2006-11-21),
3. 7109211 - Substituted benzopyran derivatives for the treatment of inflammation (2006-09-19),
4. 6998415 - Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors (2006-02-14),
5. 6951949 - Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation (2005-10-04),
6. 6875785 - Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors (2005-04-05),
7. 6822102 - Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2 mediated disorders (2004-11-23),
8. 6815460 - Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors (2004-11-09),
9. 6809111 - Prodrugs of COX-2 inhibitors (2004-10-26),
10. 6806288 - Substituted benzopyran derivatives for the treatment (2004-10-19),
11. 6753344 - Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors (2004-06-22),
12. 6716991 - Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation (2004-04-06),
13. 6696477 - Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors (2004-02-24),
14. 6677364 - Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors (2004-01-13),
15. 6613790 - Prodrugs of COX-2 inhibitors (2003-09-02),

Title: Jeffery S Carter: Pioneering Innovator in the World of Technology

Introduction:

Jeffery S Carter, a visionary inventor based in Chesterfield, MO (US), is renowned for his unwavering commitment to innovation and pursuit of excellence. With a remarkable portfolio of 34 patents, his groundbreaking work continues to shape the realm of technology and inspire future generations of inventors.

Latest Patents:

Among his latest patents is the "Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors," which highlights the efficacy of prodrugs in treating inflammation and related disorders. Additionally, his invention of "Substituted benzopyran derivatives for the treatment of inflammation" introduces a novel class of compounds for addressing cyclooxygenase-2 mediated disorders.

Career Highlights:

Jeffery S Carter's illustrious career includes significant contributions at renowned companies such as G.D. Searle & Company and Pharmacia Corporation. His innovative spirit and technical expertise have been instrumental in driving advancements in the pharmaceutical and technology sectors.

Collaborations:

Throughout his career, Jeffery S Carter has collaborated with esteemed professionals in the field, including Matthew James Graneto and John Jeffrey Talley. These collaborations have fostered a culture of creativity and ingenuity, leading to groundbreaking inventions with far-reaching impacts.

Conclusion:

In conclusion, Jeffery S Carter's exceptional passion for innovation and dedication to excellence have established him as a pioneering figure in the world of technology. His invaluable contributions not only reflect his immense talent but also serve as a beacon of inspiration for aspiring inventors worldwide, leaving a lasting legacy that continues to shape the future of technological advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…